VER
Vascular & Endovascular Review

Quinazoline Derivatives as Potential Therapeutic Agents in Breast Cancer, Cervical Cancer, and Ovarian Cancer Therapy

A Venkata Badarinath[1], Naveen Kumari K2, Gauri Nilesh Deodhar[3], B. Geetha[4], Namrata A. Muddalwar[5], Lalchand D Devhare[6] , M. S. Divya Sree[7] , Dhammshila L Devhare[8]

[1]Department of Pharmaceutics, Santhiram College of Pharmacy, Autonomous, NAAC Accredited with A+, NH 40, Nerawada, Nandyal 518112, Nandyal, A.P.
[2]Department of Pharmacology, Krishna Teja Pharmacy College, Chadalawada Nagar, Renigunta Road, Tirupathi, Andhra Pradesh 517506
[3],5G.H.Raisoni Institute of Life Sciences Hingna Wadi Link Road ,Shradha Park,Nagpur-440016
[4]SNS College Of Pharmacy And Health Sciences Coimbatore 641035 Tamilnadu.
[6]Nagpur College of Pharmacy, Wanadongri, Hingna Road, Nagpur, Maharashtra Inda 441110
[7]Department of Pharmacognosy, Krishna Teja Pharmacy College, Chadalawada nagar, Renigunta road, Tirupati – 517506, Tirupati (Dist), Andhra Pradesh
[8]Community Health Officer, Aarogya Mandir (Sub Center), Nandagomukh, NRHM, Zilla Parishad Nagpur, Kelwad, Saoner, Maharshtra
Corresponding Author: Naveen Kumari K
naveena.konipineni@gmail.com

ABSTRACT

Quinazoline derivatives have garnered attention as potential therapeutic candidates in breast cancer, cervical cancer, and ovarian cancer treatment due to their diverse molecular structures and promising pharmacological activities. This review aims to comprehensively explore the mechanisms of action, pharmacological profiles, and current research landscape of quinazoline derivatives in oncology. A systematic literature review was performed to collect studies relevant to the application of quinazoline derivatives in cancer therapy. Searches were conducted in databases such as PubMed, Scopus, and Web of Science using keywords related to quinazoline derivatives, breast cancer, cervical cancer, ovarian cancer, pharmacology, preclinical studies, and clinical trials.Quinazoline derivatives exhibit a wide range of structural diversity, contributing to their versatile pharmacological activities in cancer therapy. Mechanistically, these derivatives interact with key molecular targets complicated in cancer cell propagation, apoptosis, angiogenesis, and metastasis. Preclinical observations have demonstrated their efficacy in inhibiting tumor growth and metastatic spread across various cancer models. Clinical trials have shown promising results regarding their safety profiles and therapeutic efficacy in cancer patients, although challenges such as pharmacokinetic limitations and resistance mechanisms persist. In conclusion, quinazoline derivatives are promising compounds with significant potential in breast, cervical, and ovarian cancer therapy. Their multifaceted mechanisms of action and encouraging preclinical and clinical data underscore their role as valuable candidates for further development as anticancer agents. Addressing current challenges and exploring innovative research avenues, such as combination therapies and targeted delivery systems, are crucial steps towardyoking the full beneficialprobability of quinazoline derivatives in oncology.

KEYWORDS: Breast cancer, Cervical cancer, Ovarian cancer, Pharmacological activities, Quinazoline derivatives.

How to Cite: A Venkata Badarinath, Naveen Kumari K, Gauri Nilesh Deodhar, B. Geetha, Namrata A. Muddalwar, Lalchand D Devhare, M. S. Divya Sree, Dhammshila L Devhare, (2025) Quinazoline Derivatives as Potential Therapeutic Agents in Breast Cancer, Cervical Cancer, and Ovarian Cancer Therapy, Vascular and Endovascular Review, Vol.8, No.8s, 65-76.

INTRODUCTION

Quinazoline derivatives are a class of heterocyclic organic amalgams characterized by a fused bicyclic ring system composed of a benzene ring and a pyrimidine ring. The quinazoline scaffold serves as the core structure for these derivatives, which can be further modified to enhance their pharmacological properties[1]. Quinazoline and its derivatives have extendednoteworthydevotionto medicinal chemistry due to their variedbioticactions and impending therapeutic claims, particularly in oncology. The core structure of quinazoline derivatives consists of two fused rings[2]:

- **Benzene Ring:** A six-membered aromatic ring.
- **Pyrimidine Ring:** A six-membered ring with two nitrogen atoms at positions 1 and 3.

This fused bicyclic structure provides a versatile framework that can be modified at various positions to produce a wide range of derivatives with different biological activities[3].

1.1. Breast Cancer

It is one of the most common distortionsdistressingfemalesglobally, with importantindisposition and death rates. It arises from

the cells lining the ducts or lobules of the breast tissue, and its progression is driven by various genetic and environmental factors[4]. Key molecular targets in breast cancer include estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), which showdecisiveparts in tumor growth and proliferation. Despite advances in early detection and treatment, including surgery, radiation, chemotherapy, and targeted therapies, challenges such as drug resistance, recurrence, and metastasis persist[5]. The development of novel therapeutic agents, like quinazoline derivatives that target specific pathways convoluted in breast cancer cell survival and growth, offers hope for more effective and personalized treatment strategies, potentially improving outcomes and quality of life for patients[6].

1.2. Cervical Cancer

Cervical cancer primarily affects the cells lining the cervix, and uterus, and is predominantly caused by tenaciouscontagion with high-risk human papillomavirus (HPV) types. It remains a major public health issue, chiefly in low- and middle-income states where screening and vaccination programs are less accessible[7]. Early-stage cervical cancer is often asymptomatic, making systematic screening over Pap smears and HPV testing vital for early finding. Treatment options vary based on the stage of the disease and include surgery, radiation, and chemotherapy. However, advanced cervical cancer often presents challenges, such as resistance to standard treatments and poor prognosis. Targeted therapies, including quinazoline derivatives that inhibit key pathways like epidermal growth factor receptor (EGFR), are being explored to improve therapeutic efficacy and overcome resistance, potentially offering new hope for patients with advanced or recurrent cervical cancer[8].

1.3. Ovarian Cancer

Ovarian cancer is a lethal gynecologic malignancy that typically originates from the epithelial cells covering the ovary. It is often analyzed at a progressive stage due to the lack of exact symptoms and effective early screening methods, resulting in a poor prognosis. The standard treatment for ovarian cancer comprises surgical debulking shadowed by platinum-based chemotherapy. Despite initial responsiveness, many patients experience relapse and develop resistance to chemotherapy[9]. Molecular targets such as BRCA mutations and HER2 overexpression are significant in the development and progression of ovarian cancer. Quinazoline derivatives, which can target these and other pathways intricate in tumor growth, angiogenesis, and metastasis, offer a promising avenue for improving treatment outcomes. By providing more precise and effective treatment options, these compounds hold the potential to enhance survival rates and quality of life for ovarian cancer patients[10].

Cancer remains one of the most pressing challenges to global health, necessitating a continuous exploration of novel therapeutic strategies to combat its complexity and variability. In this context, quinazoline derivatives have emerged as particularly compelling candidates for anticancer therapy. These compounds are characterized by their versatile chemical structures and exhibit potent biological activities that make them attractive for therapeutic development. Their ability to target precise molecular lanesof cancer proliferation, angiogenesis, and metastasis underscores their potential utility in personalized medicine approaches[11].

This review focuses specifically on the applications of quinazoline derivatives in the treatment of breast cancer, cervical cancer, and ovarian cancer. By concentrating on these malignancies, each with distinct molecular profiles and clinical challenges, the review aims to offer a completeindication of how quinazoline derivatives can be harnessed to address specific aspects of cancer biology. This includes their mechanisms of action at the molecular level, their potential synergies with existing therapies, and their role in overcoming resistance mechanisms observed in traditional cancer treatments[12].

Furthermore, the review explores the current research landscape surrounding quinazoline derivatives, highlighting key preclinical studies that demonstrate their efficacy in inhibiting tumor growth and metastasis. It also examines the outcomes of clinical trials, offering insights into their safety profiles, pharmacokinetics, and therapeutic efficacy in cancer patients. Despite these advancements, challenges such as optimizing drug delivery systems and identifying biomarkers for patient stratification remain critical areas for future investigation[13].

By elucidating the unique attributes of quinazoline derivatives and their evolving role in oncology, this review aims to contribute to the understanding of how these compounds may shape the future of cancer treatment. Ultimately, by leveraging their diverse mechanisms of action and potential for targeted therapy, quinazoline derivatives hold promise in improving outcomes for patients with breast cancer, cervical cancer, and ovarian cancer, thereby advancing the field towards more effective and personalized cancer care strategies[14].

CHEMISTRY AND STRUCTURAL DIVERSITY

Quinazoline derivatives possess a broad spectrum of chemical structures that underpin their diverse pharmacological properties. This section examines the structural modifications and synthetic strategies used to bolster their effectiveness and specificity in targeting cancer cells. It emphasizes pivotal structural characteristics and their influence on biological activities, showcasing recent drug design and development strides.The versatility of quinazoline derivatives lies in their structural adaptability, which allows for tailored modifications aimed at enhancing their pharmacokinetic profiles and biological interactions. Synthetic methodologies, including substitution patterns, ring fusion strategies, and side chain variations, are explored for their role in fine-tuning therapeutic efficacy and reducing off-target effects. By optimizing these structural parameters, researchers aim to achieve enhanced selectivity for cancerous tissues while minimizing systemic toxicity[15].

Key structural features crucial to their biological activities, such as interactions with specific molecular targets tangled in cancer signaling pathways (e.g., receptor tyrosine kinases, angiogenic factors, and DNA repair enzymes), are highlighted[16]. Advances in

computational modeling and structure-activity relationship studies aid in predicting and optimizing these interactions, guiding the rational design of more potent quinazoline derivatives[17] (Table 1).

Recent innovations in drug delivery systems, such as nanoparticle formulations and targeted drug conjugates, further augment the therapeutic potential of quinazoline derivatives. These advancements aim to overcome barriers such as poor aqueous solubility and rapid metabolism, thereby improving bioavailability and tissue-specific accumulation[18].

Table 1: Organicbuildings of quinazoline derivatives.

Structure	R1	R2	R3
	-CH_3		-
	-OCH_3		-
	-CH_3	-$(CH_2)_3CH_3$	-
	-CH_3	-$(CH_2)_3CH_3$	-CH_2CH_3
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	
	-CH_3	-$(CH_2)_3CH_3$	

	$-CH_3$	$-(CH_2)_3CH_3$	
	$-CH_3$	$-(CH_2)_3CH_3$	
	$-CH_3$	$-(CH_2)_3CH_3$	3-(Phthalimido-2-yl)propyl
	$-CH_3$		
	$-CH_3$		
	$-CH_3$		
	$-CH_3$		7-Nitro-benzoxadiazole
	$-CH_3$		3-(Phthalimido-2-yl)propyl
	$-O-CH_3$		3-(Phthalimido-2-yl)propyl
	$-O-CH_3$		
	$-CH_3$	$-(CH_2)_3CH_3$	
	$-CH_3$		
	$-CH_3$		-

MECHANISMS OF ACTION

Quinazoline derivatives exhibit several key properties and mechanisms of action that make them valuable in drug development.

3.1. Inhibition of Tyrosine Kinases

Many quinazoline derivatives act as inhibitors of tyrosine kinases, enzymes that play a crucial role in the signaling pathways regulating cell division, survival, and proliferation. By inhibiting these enzymes, quinazoline derivatives can effectively halt the growth of cancer cells[19].

3.2. Targeting EGFR and HER2

Some quinazoline derivatives are specifically designed to target the EGFR and HER2, which are overexpressed in various cancers, including breast, lung, and ovarian cancers[20].

3.3. Angiogenesis Inhibition

Certain quinazoline derivatives inhibit angiogenesis, the process of new blood vessel formation that is crucial for tumor growth and metastasis. By disrupting this process, these compounds can effectively starve tumors of the necessary nutrients and oxygen, impeding their growth and spread[21].

3.4. Induction of Apoptosis

Quinazoline derivatives can induce apoptosis in cancer cells, thereby reducing tumor size and preventing cancer progression. This ability to trigger cell death in cancerous cells makes them valuable agents in the fight against various types of cancer[22].

QUINAZOLINE DERIVATIVES USED IN BREAST CANCER THERAPY

Quinazoline derivatives have shown significant potential as therapeutic agents in the dealing of breast cancer. Their diverse molecular structures and mechanisms of action make them suitable for targeting various pathways tangled in cancer progression. Below, we explore some of the key quinazoline derivatives used in breast cancer therapy, highlighting their mechanisms and clinical significance[23].

4.1. Gefitinib (Iressa)

Gefitinib has been particularly effective in patients with EGFR mutations. It has been used to treat breast cancer patients with specific genetic profiles that predict responsiveness to EGFR inhibition[24].

Mechanism of Action

Gefitinib functions as an inhibitor of EGFR tyrosine kinase. It binds to the ATP-binding site on the EGFR tyrosine kinase, blocking its activity. This blockade stops the phosphorylation and activation of downstream signaling proteins that are essential for cell proliferation and survival, thus inhibiting cancer cell growth[25].

4.2. Erlotinib (Tarceva)

Erlotinib has shown efficacy in breast cancer treatment, particularly in combination with other therapeutic agents. It is often used in patients who have developed resistance to other treatments[26].

Mechanism of Action

Similar to gefitinib, erlotinib is an EGFR tyrosine kinase inhibitor. It obstructs the signal transduction pathways that are crucial for the proliferation and survival of cancer cells[27].

4.3. Lapatinib (Tykerb)

Lapatinib is particularly effective in treating HER2-positive breast cancer, a subtype categorized by the overexpression of the HER2 protein.It is often used in combination with other treatments such as chemotherapy or hormonal therapy[28].

Mechanism of Action

Lapatinib is a dual tyrosine kinase inhibitor that targets both EGFR and HER2. It binds to the intracellular domain of these receptors, inhibiting their kinase activity and subsequent signaling pathways[29].

4.4. Afatinib (Gilotrif)

Afatinib has shown promise in preclinical and clinical studies for treating HER2-positive breast cancer. Its ability to inhibit manifoldassociates of the ErbB clan makes it a potent agent against various subtypes of breast cancer[30].

Mechanism of Action

Afatinib is a permanent inhibitor of the ErbB-type receptors, which include EGFR, HER2, and HER4. By irreversibly binding to these receptors, afatinib prevents the start of downstream gesturinglanes that endorse tumor growth[31].

4.5. Vandetanib (Caprelsa)

Although primarily used for medullary thyroid cancer, vandetanib has shown potential in breast cancer due to its anti-angiogenic and anti-proliferative effects. Its role in breast cancer therapy is currently being explored in clinical trials[32].

Mechanism of Action

Vandetanib is a multi-kinase suppressor that boards VEGFR (vascular endothelial growth factor receptor), EGFR, and RET tyrosine kinases. It inhibits angiogenesis and tumor cell proliferation[33].

QUINAZOLINE DERIVATIVES USED IN CERVICAL CANCER THERAPY

Quinazoline products have arisen as talented agents in the treatment of cervical cancer due to their aptitude to target various molecular pathways tortuous in cancer progression. Below, we highlight some of the key quinazoline derivatives used in cervical cancer therapy, emphasizing their mechanisms of action and clinical significance[34].

5.1 Erlotinib (Tarceva)

Erlotinib has been studied in cervical cancer, particularly for its potential to enhance the effects of radiation therapy. By inhibiting EGFR, erlotinib can sensitize cancer cells to radiation, potentially improving treatment outcomes[35].

Mechanism of Action

Erlotinib is an EGFR tyrosine kinase suoressor. It blocks the ATP-binding site of the EGFR tyrosine kinase, preventing the phosphorylation and initiation of lower gesturing proteins intricate in cell proliferation and survival[36].

5.2. Gefitinib (Iressa)

Similar to erlotinib, gefitinib has shown potential in amalgamation with furtheractions such as radiation and chemotherapy. Studies have explored its use in patients with progressive or regular cervical cancer, aiming to recoverretorttolls and prolong existence[37].

Mechanism of Action

Gefitinib also targets the EGFR tyrosine kinase, inhibiting its activity and subsequent signaling pathways that promote cancer cell proliferation and survival[38].

5.3. Lapatinib (Tykerb)

It has been examined in cervical cancer, particularly for its latent to treat HER2-positive tumors. Although HER2 overexpression is less common in cervical cancer compared to breast cancer, targeting this pathway can be beneficial for patients with HER2-positive cervical cancer[39].

Mechanism of Action

It is a twin tyrosine kinase suppressor that targets both EGFR and HER2. By inhibiting these receptors, lapatinib disrupts manifoldgesturingpathscomplicated in cancer cell development and existence[40].

5.4. Afatinib (Gilotrif)

Afatinib's ability to inhibit multiple members of the ErbB family makes it a promising candidate for treating cervical cancer, especially in cases where tumors exhibit resistance to other EGFR inhibitors[41].

Mechanism of Action

Afatinib irreversibly inhibits the ErbB group of receptors, including EGFR, HER2, and HER4. This broad inhibition prevents the instigation of signaling lanes that endorse tumor progress and survival[42].

5.5. Vandetanib (Caprelsa)

Vandetanib has shown potential in cervical cancer by inhibiting angiogenesis and reducing tumor growth. Its role in cervical cancer therapy is currently being explored in clinical trials, with a focus on its combination with other therapeutic agents[43].

Mechanism of Action

It is a multi-kinase suppressor that targets VEGFR, EGFR, and RET tyrosine kinases. By inhibiting these targets, vandetanib disrupts angiogenesis and tumor cell explosion[44].

QUINAZOLINE DERIVATIVES USED IN OVARIAN CANCER THERAPY

Quinazoline spinoffs have addeddevotion as potential therapeutic agents in the treatment of ovarian cancer. Their ability to delay key molecular pathstangled in cancer cell proliferation, survival, and metastasis makes them promising candidates for ovarian cancer therapy. Below, we highlight some of the key quinazoline derivatives used in ovarian cancer treatment, focusing on their mechanisms of action and clinical significance[45].

6.1. Erlotinib (Tarceva)

Erlotinib has been studied in ovarian cancer, often blended with other chemotherapeutic agents. Clinical trials have investigated its use in patients with progressive or repeated ovarian cancer, aiming to improve response rates and survival outcomes[46].

Mechanism of Action

Erlotinib is an EGFR tyrosine kinase inhibitor. It binds to the ATP-binding site of EGFR, inhibiting its activation and downstream signaling pathways that drive cancer cell proliferation and survival[47].

6.2. Gefitinib (Iressa)

Gefitinib has been evaluated in ovarian cancer for its potential to enhance the efficacy of existing treatments. Studies have explored its use along with chemotherapy and other targeted therapies, particularly in patients with EGFR mutations[48].

Mechanism of Action
Gefitinib also targets the EGFR tyrosine kinase, preventing its activation and subsequent signaling pathways that promote tumor growth[49].

6.3. Lapatinib (Tykerb)
Lapatinib has shown promise in the treatment of ovarian cancer, especially in cases where tumors exhibit overexpression of HER2. Its dual inhibition mechanism provides a broader approach to targeting ovarian cancer cells[50].

Mechanism of Action
Lapatinib is a dual tyrosine kinase inhibitor that targets both EGFR and HER2. By inhibiting these receptors, lapatinib disrupts multiple signaling pathways tangled in cancer cell proliferation and survival[51].

6.4. Afatinib (Gilotrif)
Afatinib has been explored in ovarian cancer for its potential to overcome resistance to other EGFR inhibitors. Its ability to inhibit multiple members of the ErbB family makes it a versatile agent in the treatment of ovarian cancer[52].

Mechanism of Action
Afatinib is an irreversible inhibitor of the ErbB family of receptors, including EGFR, HER2, and HER4. By binding irreversibly to these receptors, afatinib blocks the signaling pathways essential for cancer cell growth and survival[53].

6.5. Vandetanib (Caprelsa)
Vandetanib has shown potential in ovarian cancer by inhibiting the formation of new blood vessels that supply the tumor with nutrients and oxygen. Clinical trials are ongoing to evaluate its efficacy and safety along with other therapeutic agents[54].

Mechanism of Action
It is a multi-kinase inhibitor that targets VEGFR, EGFR, and RET tyrosine kinases. By inhibiting these targets, vandetanib reduces angiogenesis and tumor cell propagation[55].

CHALLENGES AND FUTURE PERSPECTIVES

Despite the significant strides in research, the clinical translation of quinazoline derivatives into mainstream cancer therapies faces several challenges that warrant consideration. One primary obstacle is their pharmacokinetic limitations, including issues related to bioavailability, distribution, metabolism, and excretion. Optimizing these pharmacokinetic properties is crucial to achieving therapeutic concentrations at tumor sites while minimizing systemic toxicity. Another critical challenge is the emergence of resistance mechanisms against quinazoline derivatives, which can diminish their efficacy over time. Cancer cells may develop mechanisms such as up regulation of drug efflux pumps, changes in drug targets, or activation of substitute signaling pathways to evade treatment effects[56]. Overcoming these resistance mechanisms requires innovative strategies, such as arrangement therapies that target multiple pathways simultaneously or the development of next-generation derivatives that circumvent resistance mechanisms. Adverse effects associated with quinazoline derivatives also pose significant concerns, potentially impacting patient adherence and quality of life. Strategies to mitigate these effects include refining drug delivery systems to enhance tumor-specific targeting and reduce off-target effects. Nanotechnology-based approaches, for instance, offer promise in improving drug delivery efficiency and reducing systemic toxicity by encapsulating quinazoline derivatives in nanoparticles tailored for tumor-specific accumulation. Future research directions should prioritize the exploration of groupingtreatments that leverage the synergistic effects of quinazoline derivatives with other therapeutic agents, such as cytotoxic drugs, immunotherapies, or targeted therapies. By combining agents that target complementary pathways or mechanisms of resistance, researchers can enhance treatment efficacy and potentially overcome resistance issues. Moreover, personalized medicine approaches based on biomarker-driven strategies hold significant promise in optimizing the use of quinazoline derivatives. Identifying predictive biomarkers that correlate with treatment response or resistance allows for tailored treatment regimens that maximize therapeutic benefit while minimizing unnecessary exposure for non-responders[57-121].

CONCLUSION

Quinazoline derivatives represent a diverse and promising class of compounds poised to make significant strides in breast cancer, cervical cancer, and ovarian cancer therapy. Their multifaceted mechanisms of action, ranging from inhibition of key signaling pathways to induction of apoptosis and suppression of angiogenesis, highlight their potential as potent anticancer agents. Encouraging findings from both preclinical and clinical studies underscore the therapeutic promise of quinazoline derivatives. In preclinical models, these compounds have demonstrated robust anti-proliferative effects, the ability to induce cancer cell death, and efficacy in preventing metastatic spread. Clinical trials have further validated their safety profiles and shown promising outcomes in terms of tumor response and patient survival rates. Despite these advancements, several challenges remain, including pharmacokinetic limitations, the development of resistance mechanisms, and potential adverse effects. Addressing these challenges through targeted drug delivery systems, innovative combination therapies, and personalized medicine approaches is crucial to maximizing the clinical utility of quinazoline derivatives. This review consolidates current knowledge and emphasizes the evolving landscape of quinazoline derivatives as pivotal agents in oncology. By highlighting their diverse mechanisms of action and discussing ongoing research efforts, it aims to guide future investigations and clinical practices aimed at optimizing

their use in the treatment of breast cancer, cervical cancer, ovarian cancer, and potentially other cancers. Continued research endeavors are vital to unlocking the full therapeutic potential of quinazoline derivatives and ultimately improving outcomes for cancer patients worldwide.

ACKNOWLEDGMENTS

None

REFERENCES

1. Amrutkar RD, Amrutkar SV, Ranawat MS. Quinazolin-4-one: A varsatile molecule. Current Bioactive Compounds. 2020;16(4):370-82.
2. Pola S. Significance of thiazole-based heterocycles for bioactive systems. Scope of selective heterocycles from organic and pharmaceutical perspective. 2016;1:13-62.
3. Ram VJ, Sethi A, Nath M, Pratap R. The chemistry of heterocycles: nomenclature and chemistry of three to five membered heterocycles: Elsevier; 2019.
4. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA: a cancer journal for clinicians. 2022;72(6):524-41.
5. Weth FR, Hoggarth GB, Weth AF, Paterson E, White MP, Tan ST, et al. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer. 2024;130(5):703-15.
6. Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers. 2022;14(5):1253.
7. Podwika SE, Duska LR. Top advances of the year: cervical cancer. Cancer. 2023;129(5):657-63.
8. Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The lancet global health. 2023;11(2):e197-e206.
9. Young RC. Early-stage ovarian cancer: to treat or not to treat. Oxford University Press; 2003. p. 94-5.
10. Ma H, Tian T, Cui Z. Targeting ovarian cancer stem cells: a new way out. Stem Cell Research & Therapy. 2023;14(1):28.
11. DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. Journal of Clinical Oncology. 2023;41(3):609-17.
12. Wallis B, Bowman KR, Lu P, Lim CS. The challenges and prospects of p53-based therapies in ovarian cancer. Biomolecules. 2023;13(1):159.
13. Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. British Journal of Cancer. 2023;128(2):342-53.
14. González-Martín A, Harter P, Leary A, Lorusso D, Miller R, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Annals of Oncology. 2023;34(10):833-48.
15. Ahad HA, Rani EM, Kranthi G, Gupta PR, Reddy MN, Prakash G. Spectrophotometric Determination of Cefadroxil in Cefadroxil Tablets by Bromination Method. Analytical Chemistry Letters. 2011;1(2):185-8.
16. Nizamuddin N, Ahad HA. Nayakanti Devanna, Molecular Docking studies of N-Methyl-2, 3-Disubstituted Quinazolin-4-Ones Scaffold..(2020). Int J Life Sci Pharma Res.10(5):P102-10.
17. Jafari E, Khajouei MR, Hassanzadeh F, Hakimelahi GH, Khodarahmi GA. Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities. Research in pharmaceutical sciences. 2016;11(1):1-14.
18. Selvam TP, Kumar PV. Quinazoline marketed drugs. Research in Pharmacy. 2015;1(1).
19. Zayed MF. Medicinal chemistry of quinazolines as anticancer agents targeting tyrosine kinases. Scientia Pharmaceutica. 2023;91(2):18.
20. Ravez S, Castillo-Aguilera O, Depreux P, Goossens L. Quinazoline derivatives as anticancer drugs: a patent review (2011–present). Expert opinion on therapeutic patents. 2015;25(7):789-804.
21. Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, et al. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties. European journal of medicinal chemistry. 2013;67:373-83.
22. Li Y, Xiao J, Zhang Q, Yu W, Liu M, Guo Y, et al. The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton. Bioorganic & Medicinal Chemistry. 2019;27(3):568-77.
23. El-Azab AS, Alaa A-M, AlSaif NA, Alkahtani HM, Alanazi MM, Obaidullah AJ, et al. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. Bioorganic Chemistry. 2020;104:104345.
24. Șandor A, Ionuț I, Marc G, Oniga I, Eniu D, Oniga O. Structure–activity relationship studies based on quinazoline derivatives as EGFR kinase inhibitors (2017–present). Pharmaceuticals. 2023;16(4):534.
25. Bhatia P, Sharma V, Alam O, Manaithiya A, Alam P, Alam MT, et al. Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019). European Journal of Medicinal Chemistry. 2020;204:112640.
26. Lipunova GN, Nosova EV, Charushin VN, Chupakhin ON. Synthesis and antitumour activity of 4-aminoquinazoline

derivatives. Russian Chemical Reviews. 2016;85(7):759.
27. Bansal R, Malhotra A. Therapeutic progression of quinazolines as targeted chemotherapeutic agents. European Journal of Medicinal Chemistry. 2021;211:113016.
28. Sharma VK, Barde A, Rattan S. A short review on synthetic strategies towards quinazoline based anticancer drugs. ARKIVOC: Online Journal of Organic Chemistry. 2021;2021.
29. Das D, Hong J. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. European Journal of Medicinal Chemistry. 2019;170:55-72.
30. Kumar S, Agrawal R. Next generation tyrosine kinase inhibitor (TKI): afatinib. Recent patents on anti-cancer drug discovery. 2014;9(3):382-93.
31. Dungo RT, Keating GM. Afatinib: first global approval. Drugs. 2013;73:1503-15.
32. Degrauwe N, Sosa JA, Roman S, Deshpande HA. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clinical Medicine Insights: Oncology. 2012;6:CMO. S7999.
33. Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, et al. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Expert Review of Anticancer Therapy. 2016;16(11):1109-18.
34. Marzaro G, Guiotto A, Chilin A. Quinazoline derivatives as potential anticancer agents: a patent review (2007–2010). Expert opinion on therapeutic patents. 2012;22(3):223-52.
35. Cruz-Lopez O, Conejo-Garcia A, C Nunez M, Kimatrai M, E Garcia-Rubino M, Morales F, et al. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. Current medicinal chemistry. 2011;18(7):943-63.
36. Liu LT, Yuan T-T, Liu H-H, Chen S-F, Wu Y-T. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors. Bioorganic & medicinal chemistry letters. 2007;17(22):6373-7.
37. Jeong CW, Son BW, Du Ha J, Kim G-D. Novel Quinazoline Derivatives Targeting on EGFR Kinase Mediated Signal Pathway in A431 Human Epidermoid Carcinoma Cells. 생명과학회지. 2011;21(3):349-57.
38. Yin K-H, Hsieh Y-H, Sulake RS, Wang S-P, Chao J-I, Chen C. Optimization of gefitinib analogues with potent anticancer activity. Bioorganic & Medicinal Chemistry Letters. 2014;24(22):5247-50.
39. Rusnak D, Alligood K, Mullin Ra, Spehar G, Arenas-Elliott C, Martin AM, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines. Cell proliferation. 2007;40(4):580-94.
40. Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer. Clinical therapeutics. 2009;31:2332-48.
41. Keating GM. Afatinib: a review in advanced non-small cell lung cancer. Targeted oncology. 2016;11:825-35.
42. Yang P-Y, Tai C-J. Chinese Medicine Treatment for Afatinib-Induced Paronychia. Case reports in oncological medicine. 2017;2017(1):7327359.
43. Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M. Vandetanib for the treatment of medullary thyroid carcinoma. Annals of Pharmacotherapy. 2014;48(3):387-94.
44. Phadnis S, Wang X, Daw N, Herzog CE, Subbiah I, Zaky W, et al. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO open. 2023;8(6):101609.
45. Li J, Meng Y, Liu Y, Feng Z-Q, Chen X-G. F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies. Investigational new drugs. 2010;28:132-8.
46. Comis RL. The current situation: erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer. The oncologist. 2005;10(7):467-70.
47. Abdelgalil AA, Al-Kahtani HM, Al-Jenoobi FI. Erlotinib. Profiles of Drug Substances, Excipients and Related Methodology. 45: Elsevier; 2020. p. 93-117.
48. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839)(Iressa®) tablets. The oncologist. 2003;8(4):303-6.
49. Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. British journal of cancer. 2004;90(3):566-72.
50. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nature reviews drug discovery. 2007;6(6).
51. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in lapatinib (Tykerb, GW572016) disposition and drug interactions. Drug Metabolism and Disposition. 2008.
52. Wang M, Chang AY-C. Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells. Oncotarget. 2018;9(23):16533.
53. Köhler J, Schuler M. LUX-Lung 3: Redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. Future Oncology. 2014;10(4):533-40.
54. Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clinical Cancer Research. 2013;19(3):524-9.
55. Al-Ghusn AI, Bakheit AH, Attwa MW, AlRabiah H. Vandetanib. Profiles of Drug Substances, Excipients and Related Methodology. 2023;48:109-34.
56. Wahan SK, Sharma B, Chawla PA. Medicinal perspective of quinazolinone derivatives: Recent developments and structure–activity relationship studies. Journal of Heterocyclic Chemistry. 2022;59(2):239-57.
57. Li H, Fu G, Zhong W. Natural quinazolinones: From a treasure house to promising anticancer leads. European Journal of Medicinal Chemistry. 2023;245:114915.

58. Salpe, H. G., Devhare, L. D., Ghugare, A. P., & Singh, N. (2016). Formulation and evaluation of hpmc coated diltiazem hcl tablet and its comparison with other marketed preparation. Research chronicle in health sciences, 3(1), 11-17.
59. Devhare, L., Hiradeve, S., & Bobade, T. (2017). Method Development & Validation For Determination Of Water Content. LAP LAMBERT Academic Publishing.
60. Devhare, L. D., Ghugare, A. P., Hatwar, B. P., Goupale, D. C., & Devhare, L. D. (2015). Method development for determination of water content from various materials by spectrophotometry and it's validation. International journal of drug delivery, 7(4), 233-240.
61. Tonde, T. U., Kasliwal, R. H., & Devhare, L. D. (2016). Quantitative estimation of bacoside a in polyherbal memory enhancer syrup for memory boosting activity using hptlc method. Research chronicle in health sciences, 2(6), 315-320.
62. Ghugare, A. P., Devhare, L., & Hatwar, B. P. (2016). Development and validation of analytical methods for the simultaneous estimation of Nimorazole and Ofloxacin in tablet dosage form. International Journal of Drug Delivery, 8, 96-98
63. Makhani, A. A., & Devhare, L. (2017). Development and validation of vierordt's spectrophotometric method for simultaneous estimation of Drotaverine and Nimesulide combination. Research chronicle in health sciences, 3(2), 22-28
64. Makhani, A. A., & Devhare, L. D. (2017). Development and validation of analytical methods for drotaverine and nimesulide combination. Research chronicle in health sciences, 3(3), 40-44.
65. Katole, G., & Devhare, L. (2018). Diluent and granulation study on Metformin Hydrochoride. LAP LAMBERT Academic Publishing.
66. Katole, G., & Devhare, L. D. (2020). Recent insight into some emerging natural resources with remarkable hepato protective potentials. International journal of pharmaceutical science and research, 5(1), 41-47.
67. Devhare, L. D., & Gokhale, N. (2021). Acid neutralizing capacity and antimicrobial potential of selected solvent extract from various indigenous plants. Journal of Advanced Scientific Research, 12(04), 175-179
68. Uplanchiwar, V. P., Raut, S. Y., & Devhare, L. D. (2021). Pharmacological assessment of antiulcer activity of gloriosa superba linn tubers in experimentally induced gastric ulcers. Journal of medical pharmaceutical and allied science, 10(3), 2852-2856.
69. Devhare, L. D., & Gokhale, N. (2022). Antioxidant and Antiulcer property of different solvent extracts of Cassia tora Linn. Research journal of pharmacy and technology, 15(3), 1109-1113.
70. Devhare, L. D., & Gokhale, N. (2023). A brief review on: phytochemical and antiulcer properties of plants (fabaceae family) used by tribal people of gadchiroli maharashtra. International journal of pharmaceutical sciences and research, 14(4), 1572-1593.
71. Devhare, L. D., & Gokhale, N. (2023). In silico anti-ulcerative activity evaluation of some bioactive compound from Cassia tora and Butea monosperma through moleculer docking approach. International journal of pharmaceutical sciences and research, 14(2), 1000-08.
72. Suruse, P. B., Jadhav, B. A., Barde, L. G., Devhare, L. D., Singh, S., Minj, K. H., & Suman, A. (2023). Exploring the potential of Aerva Lanata extract in a herbal ointment for fungal infection treatment. Journal of Survey in Fisheries Sciences, 10(1), 1922-1932.
73. Bodhankar, S. S., Devhare, L. D., Meshram, A. S., Moharkar, D. W., & Badwaik, C. B. (2023). Formulation and in vitro evaluation of dental gel containing ethanglic extract of Mimosa pudica. European Chemical Bulletin, 12(5), 1293-1299.
74. Shende, S. M., Bhandare, P., & Devhare, L. (2023). In-vitro: micropropagation of mint and investigate the antibacterial activity of mint extract. Eur. Chem. Bull, 12(5), 780-784.
75. Singh, S., Minj, K. H., Devhare, L. D., Uppalwar, S. V., Anand, S., Suman, A., & Devhare, D. L. (2023). An update on morphology, mechanism, lethality, and management of dhatura poisoning. Eur. Chem. Bull, 12(5), 3418-3426.
76. Devhare, L. D., Bodhankar, S. S., Warambhe, P., Uppalwar, S. V., Devhare, D. L., Uchibagle, S., & Shende, S. (2023). Important role of food and nutritional security during Covid-19: A survey. Eur. Chem. Bull, 12(5), 1363-1374.
77. Gnana, R. P. M., Devhare, L. D., Dharmamoorthy, G., Khairnar, M. V., & Prasidha, R. (2023). Synthesis, Characterisation, Molecular Docking Studies and Biological Evaluation of Novel Benzothiazole Derivatives as EGFR Inhibitors for Anti-breast Cancer Agents. International Journal of Pharmaceutical Quality Assurance, 14(3), 475-480.
78. Prasad, M., Suman, A., Srivastava, S., & Devhare, L. D. (2023). Butea monosperma stem bark extract partially reverses high fat diet-induced obesity in rats. Eur. Chem. Bull, 12(5), 4267-4273.
79. Thakare, V. M., Umare, S. A., & Devhare, L. D. (2023). Separation and purification of carboxymethyl cellulose from Spinacia Oleracea for use in pharmaceutical dosage form. Eur. Chem. Bull, 12(5), 4062-4080.
80. Suruse, P. B., Deshmukh, A. P., Barde, L. G., Devhare, L. D., Maurya, V. K., Deva, V., & Priya, N. S. (2023). Rimegepant embedded fast dissolving films: A novel approach for enhanced migraine relief. Journal of Survey in Fisheries Sciences,10(1), 2071-2084.
81. Pathak, N. R., Devhare, L. D., Sawarkar, K. R., Dubey, M., Trivedi, V., Thakre, A. R., & Thakare, V. M. (2023). Aclinial reveiew on pharmacological evaluation of Thiazolidine and Isatin in the new millenium as magic moieties. Eur. Chem. Bull, 12(5), 3410-3417.
82. Nikam Nikita, R., Vaishnavi, A., & Lalchand, D. (2023). Parenteral drug delivery approach: an overview. Journal of xidian university, 17(1), 386-400.
83. Shende, S. M., Meshram, B., Karemore, H., & Devhare, L. D. (2023). Development And Characterization of Glycerogelatin Suppositories For Enhanced Efficacy. European Journal of Pharmaceutical and Medical Research, 10(6), 522-528.
84. Shukla, M., Tiware, S. A., Desai, S. R., Kumbhar, S. T., Khan, M. S., Mavai, Y., & Devhare, L. D. (2023).

Pharmacological Evaluation of Gloriosa Superba Linn Flower Extract For Antiulcer Activity. Journal of Survey in Fisheries Sciences, 10(2), 463-470.
85. Tiwari, R., Mishra, J., Devhare, L. D., & Tiwari, G. (2023). AN UPDATED REVIEW ON RECENT DEVELOPMENTS AND APPLI-CATIONS OF FISH COLLAGEN. Pharma Times, 55(06), 28.
86. Polireddy, P., Malviya, V., Arora, S., Singh, M., pooja Tanaji, G., Devhare, L. D., & Dharmamoorthy, G. (2023). Assessment of Hepatoprotective Potential of Ecbolium Linneanum Extract on Experimental Animals. Journal of Coastal Life Medicine, 11, 884-890.
87. Devhare, L. D., Kumbhar, S. T., Chitrapu, P., Kundral, S., & Borkar, A. A. (2023). In-Silico Molecular Docking Study of Substituted Imidazo 1, 3, 4 Thiadiazole Derivatives: Synthesis, Characterization, and Investigation of their Anti-Cancer Activity. Journal of Coastal Life Medicine, 11, 1237-1245.
88. Sonule, M., Devhare, L. D., Babu, M. N., Gunjal, S. D., & Varalaxmi, S. (2023). Microemulgel-based Hydrogel of Diclofenac Sodium using Lipidium sativum as a Gelling Agent. International Journal of Drug Delivery Technology, 13(4), 1235-1239.
89. Shriram, B. K., Devhare, L. D., Mehrotra, A., Deokar, S. S., & Singh, S. P. (2023). Formulation and Evaluation of Mosquito Repellent Stick. International Journal of Drug Delivery Technology, 13(4), 1283-1286.
90. Tiwari, G., Gupta, M., Devhare, L. D., & Tiwari, R. (2024). Therapeutic and phytochemical properties of thymoquinone derived from Nigella sativa. Current Drug Research Reviews Formerly: Current Drug Abuse Reviews, 16(2), 145-156.
91. Singh, M., Malik, A., Devhare, D. L., Ruikar, D. B., Krishnan, K., Kumar, D. V., & Devnani, D. (2023). Comparative Case Study On Tuberculosis Patients Between Rural And Urban Areas. Journal of Survey in Fisheries Sciences, 10(2), 1-11.
92. Thakre, S. M., Kumar, D. V., Ahuja, A., Hamid, N., Thakre, A. R., Khan, M. S., & Devhare, L. (2023). Exploring the Influence of an Antifungal Medication on Patients Receiving Oral Hypoglycemic Therapy: Investigating the Interplay Between Medications. Journal of Coastal Life Medicine, 11, 1255-1262.
93. Adimulapu, A. K., Devhare, L. D., Patil, A., Chachda, N. O., & Dharmamoorthy, G. (2023). Design and Development of Novel Mini Tablet Cap Technology for the Treatment of Cardiovascular Diseases. International Journal of Drug Delivery. Technology, 13(3), 801-806.
94. Krishna, K. V., Jain, P. K., Devhare, L. D., Sharma, R. K., Bagade, O. M., Venkatesham, A., & Yogesh, P. K. (2023). A Study on Antidiabetic Potential of Dried Fruits Extract of Eucalyptus Globulus in Experimental Animals. Journal of Biomedical Engineering, 40(3), 99-110.
95. Priya, M. G. R., Prasanth, L. M. L., Devhare, L. D., Yazdan, S. K., & Gunjal, S. (2024). Synthesis, DNA Binding, Molecular Docking and Anticancer Studies of Copper (II), Nickel (II), and Zinc (II) Complexes of Primaquine-based Ligand. International Journal of Pharmaceutical Quality Assurance, 15(1), 69-75.
96. Choudhary, R. K., Beeraka, S., Sarkar, B. K., Dharmamoorthy, G., & Devhare, L. (2024). Optimizing Verapamil Hydrochloride In-situ Delivery: A Strategic Formulation Approach using Box-Behnken Design for Enhanced Performance and Comprehensive Evaluation of Formulation Parameters. International Journal of Drug Delivery Technology, 14(1), 61-70.
97. Kumar, K. K., Kiran, V., Choudhary, R. K., Devhare, L. D., & Gunjal, S. D. (2024). Design Development and Characterization of Nicardipine Solid Lipid Nano-Particulars. International Journal of Drug Delivery Technology, 14(1), 71-78.
98. Devhare, L. D., & Gokhale, N. (2023). Extraction. Phytochemical Screening and Comparative Pharmacological Evaluation of Some Indigenous Plants for Antiulcer Activity, 01-244.
99. Devhare, L. D., Naikwadi, A. S., & Arote, S. B. (2023). Aditya V, Hiteshkumar S. Agrawal. Pharmacy Practice. Pritam Publication, 1-200.
100. Devhare, L. D., & Nikam, N. (2023). Practical Handbook of Pharmacology-II. Pritam Publication, 1, 1-95.
101. Devhare, L., & Prasad, C. (2024). Prophylactic and curative activity of Withania somnifera on experimentally induced calcium oxalate nephrolithiasis. Journal of medical pharmaceutical and allied sciences, 13(4), 6687-6695.
102. Shende, S., Devhare, L., Prasad, C., Khobragade, A., & Khapne, A. (2024). Next-Generation Drug Delivery Strategies for Personalized Healthcare. Pharmaceutical Research - Recent Advances and Trends, 2, 28-62
103. Devnani, D., Prasad, K. K., Bongade, K., Verma, A., Choudhary, T., Posa, M. K., & Devhare, D. L. (2024). Case Study On Rubella Virus. Journal of Advanced Zoology, 45(2). 1133
104. Lalchand D. Devhare, Ram Kumar Choudhary, Kiran Kumar Kurella, Falgunee Dasharath Ghadi, Jyoti Mundlia, Murali Krishna Kandukuri. (2024). Research Methodology and Biostatistics.IIP Publication.1-165
105. Kumar, Y. G., Dharmamoorthy, G., Devhare, L. D., Gunjal, S. D., & Deshpande, M. (2023). Toxicity Profile Study of Antihypertensive Drug Prazosin in Pregnant Wistar Rats. Journal of Advanced Zoology, 44, 64
106. Devhare, L. D.(2023) Extraction phytochemical screening and comparative pharmacological evaluation of some indigenous plants for antiulcer activity.Shodhganga.1-244
107. Konda V V S Krishna, Virendra Kumar Maurya, S. R. Fulmali, Praful N Giradkar, Lalchand D. Devhare (2023). A Textbook of Social and Preventive Pharmacy. Pritam Publication.1-201
108. Konda V V S Krishna, Amruta R. Patil, Anupama A. Kapadnis, Vinod M. Thakare, Lalchand D. Devhare. (2023). Textbook of Pharmacotherapeutics. Pritam Publication.1-166
109. Savita Shrikant Deokar Vedanshu R. Malviya, Biresh Kumar Sarkar, Lalchand D Devhare, Mangla Nand Singh.(2023). A Textbook of Novel Drug Delivery System. IIP Publication.1-230.
110. Chand, G., Devhare, L. D., & Hooda, T. (2024). Diverse Properties of Tinospora Cordifolia (Giloy, Heart Leaved Moonseed) world wild use for immunotherapies;boosting the body's defence and immune support . Emerging Paradigms for Antibiotic-Resistant Infections: Beyond the Pill. Sringer Nature. 471-486

111. Upreti, P., Devhare, L. D., Abdulmageed, L. H., Kumar, Y. G., Kumar, R., & Dharmamoorthy, G. (2024). Combatting Antibiotic Resistance: Leveraging Fecal Microbial transplantation for gut health. Emerging Paradigms for Antibiotic-Resistant Infections: Beyond the Pill. 211-232.
112. Chandani Prasad, Lalchand Devhare, Ashish Khobragade and Shubham Shende. (2025). Herbal Approaches To Skin Lightening: A Comprehensive Review. 16(1): 62-68.
113. Vyas S, Anitha KN, Mudduluru NB, Devhare LD. Quality by Design Approach to Nasal Mucoadhesive Microspheres: Enhanced Sumatriptan Succinate Delivery through Formulation and Characterization. International Journal of Drug Delivery Technology. 2024;14(3):1644-1651.
114. Deogade, S., Shende, S., Prasad, C., Dorlikar, M., Urade, P., & Devhare, LD. (2025). Autophagy: A Critical Review of Cellular Homeostasis and Pathophysiology. Asian Journal of Advanced Research and Reports, 19(2), 280-287.
115. Kumar, Y. G., Anitha, K. N., Verma, A., Agrawal, S. L., Motiram, N., Gawai, H. A. S., & Devhare, LD. (2025). Micro Needles Patch for Insulin: Transforming Drug Delivery in Diabetes Management. Journal of Neonatal Surgery, 14(2s).
116. Spandana, C. H. V. L. D., Anitha, K. N., Muddagoni, J., Gawai, N. M., Chauhan, V., Sawarkar, H. A., & Devhare, LD. (2025). Phytopharmaceutical Interventions in Neurodegenerative Disorders: Emerging Trends and Prospects. Journal of Neonatal Surgery, 14(2s).
117. Lalchand D. Devhare, Ram Kumar Choudhary, Kiran Kumar Kurella, Falgunee Dasharath Ghadi, Jyoti Mundlia, Murali Krishna Kandukuri. Textbook of Research Methodology and Biostatistics. IIP Publication, 2024, Volume 1, Pages 1-165.
118. Lalchand D. Devhare Konda V V S Krishna, Virendra Kumar Maurya, S. R. Fulmali, Praful N Giradkar. A Textbook of Social and Preventive Pharmacy. Pritam Publication. 2023, Volume 1, Pages 1-201.
119. Lalchand D. Devhare Konda V V S Krishna, Amruta R. Patil, Anupama A. Kapadnis, Vinod M. Thakare. Textbook of Pharmacotherapeutics. Pritam Publication. 2023, Volume 1, Pages 1-166.
120. Savita Shrikant Deokar Vedanshu R. Malviya, Biresh Kumar Sarkar, Lalchand D Devhare, Mangla Nand Singh. A Textbook of Novel Drug Delivery System. IIP Publication. 2023, Volume 1, Pages1-230.
121. Prasad, C., Devhare, LD., Khobragade, A., & Shende, S. Herbal Approaches To Skin Lightening: A Comprehensive Review. International Journal of Pharmaceutical Sciences and Research, 2025; Vol. 16(1): 62-68.